Daniela Verthelyi
Overview
Explore the profile of Daniela Verthelyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mendoza M, Ireland D, Lee H, Kelly-Baker L, Chowdhury M, Verthelyi D, et al.
Emerg Microbes Infect
. 2025 Mar;
:2477668.
PMID: 40059770
Dengue virus (DENV) is a growing global public health threat. The lack of symptomatic immune competent animal models for Dengue has hindered the screening and development of effective therapeutics that...
2.
Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X, et al.
Bioanalysis
. 2025 Jan;
17(3):105-149.
PMID: 39862111
The 18 Workshop on Recent Issues in Bioanalysis (18 WRIB) took place in San Antonio, TX, USA on May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple...
3.
Her C, Thacker S, Balsamo J, Kelley Baker L, Ireland D, Pang E, et al.
AAPS J
. 2024 Dec;
27(1):20.
PMID: 39707070
Characterizing and mitigating factors that impact product immunogenicity can aid in risk assessment and/or managing risk following manufacturing changes. For follow-on products that have the same indication, patient population, and...
4.
Jani D, Gunsior M, Marsden R, Cowan K, Irvin S, Hay L, et al.
AAPS J
. 2024 Sep;
26(5):98.
PMID: 39231893
No abstract available.
5.
Roberts B, Mattei A, Howard K, Weaver J, Liu H, Lelias S, et al.
Front Pharmacol
. 2024 Aug;
15:1363139.
PMID: 39185315
Advances in synthetic peptide synthesis have enabled rapid and cost-effective peptide drug manufacturing. For this reason, peptide drugs that were first produced using recombinant DNA (rDNA) technology are now being...
6.
Jani D, Gunsior M, Marsden R, Cowan K, Irvin S, Hay L, et al.
AAPS J
. 2024 Jul;
26(4):80.
PMID: 38992280
Immunogenicity testing and characterization is an important part of understanding the immune response to administration of a protein therapeutic. Neutralizing antibody (NAb) assays are used to characterize a positive anti-drug...
7.
Baratta M, Jian W, Hengel S, Kaur S, Cunliffe J, Boer J, et al.
Bioanalysis
. 2024 Jun;
16(9):307-364.
PMID: 38913185
The 17 Workshop on Recent Issues in Bioanalysis (17 WRIB) took place in Orlando, FL, USA on June 19-23, 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory...
8.
Lee H, Xu B, Lewkowicz A, Engel K, Kelley-Baker L, McWilliams I, et al.
EBioMedicine
. 2024 Jun;
104:105170.
PMID: 38823088
Background: Ebola virus disease (EVD) survivors experience ocular sequelae including retinal lesions, cataracts, and vision loss. While monoclonal antibodies targeting the Ebola virus glycoprotein (EBOV-GP) have shown promise in improving...
9.
Tourdot S, Baltrunkonis D, Denies S, Devanarayan V, Grudzinska-Goebel J, Kromminga A, et al.
MAbs
. 2024 Mar;
16(1):2324801.
PMID: 38441119
Biologics have revolutionized disease management in many therapeutic areas by addressing unmet medical needs and overcoming resistance to standard-of-care treatment in numerous patients. However, the development of unwanted immune responses...
10.
Mora J, Palmer R, Wagner L, Wu B, Partridge M, Meena , et al.
Bioanalysis
. 2024 Feb;
16(7):77-119.
PMID: 38389403
The 17 Workshop on Recent Issues in Bioanalysis (17 WRIB) took place in Orlando, FL, USA on June 19-23, 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory...